This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-08; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting2026-04-07